Spots Global Cancer Trial Database for Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors

Official Title: Longitudinal Metabolite Levels in Patients Receiving Maintenance PARP Inhibitors

Study ID: NCT04917744

Conditions

Ovarian Carcinoma

Interventions

Biospecimen Collection

Laboratory Biomarker Analysis

Medical Chart Review

Study Description

Brief Summary: This study evaluates blood samples and compares levels of metabolites (levels of vitamins, carbohydrates, proteins, etc., that are in the blood), before and after the plasma exchange in patients scheduled to receive immunotherapy for their ovarian cancer. The information gained from this study may help researchers better understand the side effects from each treatment and possibly lessen those side effects for future treatments.

Detailed Description: PRIMARY OBJECTIVE: I. To determine the extent to which PARP inhibitor (PARPi) treatment reduces systemic levels of mesenchymal stem cell (MSC)-derived cancer support factors in patients with cancer. OUTLINE: Patients undergo collection of blood samples prior to drug initiation, weekly thereafter for the first month of therapy, monthly for the first month, and at disease progression or after cessation of treatment to monitor for toxicity. Blood samples are analyzed. Patients' medical charts are also reviewed to determine outcomes after PARP inhibition.